Immediate Impact
40 standout
Citing Papers
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Gregory A. Durm being referenced
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
2022 Standout
417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Gregory A. Durm | 178 | 123 | 21 | 73 | 11 | 328 | |
| Teresa Curiel | 141 | 54 | 13 | 81 | 13 | 349 | |
| Anh Gia Pham | 81 | 43 | 16 | 110 | 16 | 351 | |
| Evan D. Slater | 76 | 67 | 15 | 82 | 7 | 305 | |
| Rachel Liang | 80 | 61 | 10 | 96 | 16 | 315 | |
| Meagan Miller | 78 | 97 | 12 | 99 | 15 | 292 | |
| Aldo Lourenço Abbade Dettino | 157 | 62 | 20 | 46 | 23 | 266 | |
| Yufan Huang | 91 | 46 | 7 | 69 | 26 | 323 | |
| Dawid Sigorski | 129 | 56 | 22 | 68 | 25 | 315 | |
| Mark Bates | 128 | 41 | 3 | 102 | 19 | 297 | |
| Mostafa Sarvizadeh | 81 | 65 | 14 | 96 | 19 | 282 |
All Works
Loading papers...